G20 declaration – Statements about action on AMR

Dear All:

​The G20 have released a declaration in which they specifically discuss their intent around AMR. See below a link to their .pdf on line. Here’s the key bit (bottom of page 8, top of page 9). I’ve both highlighted some key phrases and done some formatting to make it easier to read:

  • Combatting Antimicrobial Resistance (AMR): AMR represents a growing threat to public health and economic growth. To tackle the spread of AMR in humans, animals and the environment, we aim to have implementation of our National Action Plans, based on a One-Health approach, well under way by the end of 2018.
  • We will promote the prudent use of antibiotics in all sectors and strive to restrict their use in veterinary medicine to therapeutic uses alone. Responsible and prudent use of antibiotics in food producing animals does not include the use for growth promotion in the absence of risk analysis.
  • We underline that treatments should be available through prescription or the veterinary equivalent only.
  • We will strengthen public awareness, infection prevention and control and improve the understanding of the issue of antimicrobials in the environment. We will promote access to affordable and quality antimicrobials, vaccines and diagnostics, including through efforts to preserve existing therapeutic options.
  • We highlight the importance of fostering R&D, in particular for priority pathogens as identified by the WHO and tuberculosis.
  • We call for a new international R&D Collaboration Hub to maximise the impact of existing and new anti-microbial basic and clinical research initiatives as well as product development. We invite all interested countries and partners to join this new initiative.
  • Concurrently, in collaboration with relevant experts including from the OECD and the WHO, we will further examine practical market incentive options. 

To my eye, there’s a lot to like here. The idea of a coordinating hub is especially interesting as is the mention of examining market incentives. Onward!

Best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust | Follow me on Twitter: @JohnRex_NewAbx

Upcoming events of note outside of the mainstream large meetings:

  • 10-11 July: FDA workshop on bacteriophage therapies
  • 19 July: FDA workshop on combination therapy for TB
  • 5-9 Sep: ASM-ESCMID conference on antibiotic R&D, including the CARB-X + GARDP Antibiotic Bootcamp
  • 13 Sep 2017 (DC): FDA-CDRH workshop on diagnostic devices for detecting antimicrobial susceptibility & resistance

Link to G20 declaration online (4 Feb 2018 update — new links as old ones seem broken):

Share

How the sausage is made: A day of advocacy for PASTEUR

Dear All, Along with more than 50 others, I spent Tuesday 12 Sep 2023 on Capitol Hill visiting offices of members of Congress (Senate and House) seeking support for the PASTEUR Act. If you’re a regular reader, you’ll know that we now have substantial bipartisan support for PASTEUR: it was re-introduced as The Pioneering Antimicrobial

Canada says, “Let’s pull together!” in a major new report

Dear All (and with thanks to Kevin for co-authoring): Yesterday saw the release of a major new report on Pull incentives from Canada! The report’s cover art eloquently summarizes its key message: Well said … and proves that a picture really is worth 1,000 words! Here are the links you’ll need: The report’s webpage at the

€100m HERA Invest fund; Sign to support PASTEUR; Superb AMR movie!

Dear All,  Expanding the available Push funding, the EU’s HERA (Health Emergency Preparedness and Response Authority) has created HERA Invest by allocating €100m in support early and late phases of clinical trials. HERA Invest is open on a rolling application basis to EU-based SMEs developing medical countermeasures that address one of the following cross-border health threats: (i)

Scroll to Top